HIV integrase inhibitors

US8383639B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• B. Narasimhulu Naidu · Durham, US
• Kevin Peese · Haddam, US
• Ira B. Dicker · Wilmington, US
• Chen Li · South Glastonbury, US
• Manoj Patel · Berlin, US
• Nicholas A. Meanwell · East Hampton, US
• Michael A. Walker · Durham, US

Key dates

• Filing date: Oct 8, 2010
• Grant date: Feb 26, 2013
• Expiry date: Dec 4, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.